Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171183 · ClinicalTrials.gov registry record · Phase 2
Carvedilol for Psychostimulant Dependence
A Phase 2 study of Cocaine Dependence and Cocaine Withdrawal, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT01171183 is a Phase 2 study of Cocaine Dependence and Cocaine Withdrawal that has completed, run by University of Arkansas. The registered enrollment target is 32 participants, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01171183, a Phase 2 study of Cocaine Dependence and Cocaine Withdrawal, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines whether carvedilol prolongs abstinence in recently abstinent cocaine dependent participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG controlled release carvedilol
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01171183
The ClinicalTrials.gov registry entry for NCT01171183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (89% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01171183 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT01171183 about?
NCT01171183 is a clinical study titled "Carvedilol for Psychostimulant Dependence". This study examines whether carvedilol prolongs abstinence in recently abstinent cocaine dependent participants.
What is the current status of trial NCT01171183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-08. Estimated completion is 2014-05.
What conditions does trial NCT01171183 study?
This clinical trial studies the following conditions: Cocaine Dependence, Cocaine Withdrawal.
What interventions are being tested in trial NCT01171183?
The interventions under investigation include: Placebo (DRUG), controlled release carvedilol (DRUG).
Who is sponsoring clinical trial NCT01171183?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01171183 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.